(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.28%.
Lyell Immunopharma's earnings in 2025 is -$331,397,000.On average, 2 Wall Street analysts forecast LYEL's earnings for 2025 to be -$252,531,250, with the lowest LYEL earnings forecast at -$284,325,790, and the highest LYEL earnings forecast at -$220,736,711. On average, 2 Wall Street analysts forecast LYEL's earnings for 2026 to be -$261,176,291, with the lowest LYEL earnings forecast at -$303,536,992, and the highest LYEL earnings forecast at -$218,815,591.
In 2027, LYEL is forecast to generate -$261,272,347 in earnings, with the lowest earnings forecast at -$261,272,347 and the highest earnings forecast at -$261,272,347.